Objectives: This systematic review aimed to assess the efficacy of Leukocyte- and Platelet-Rich Fibrin (L-PRF) for the treatment of vascular leg ulcers. Method: Following PRISMA guidelines, a literature search was done for studies where L-PRF was used to treat vascular leg ulcers. Results: Among six included articles, a total of 76 venous leg ulcers were treated with L-PRF. None of the studies included ulcers of arterial or lymphatic origin. Fifty-seven (75.0%) of the venous ulcers completely healed at end of follow-up. Mean time to complete healing was 6.7 weeks (SD = 5.0). All non-healed ulcers showed an important reduction in wound area. No adverse effects related to L-PRF therapy were reported. Conclusions: The results suggest that L-PRF could be a safe, simple to use and effective therapeutic option for the treatment of venous leg ulcers, however, caution is advised as the results are based on small sample sizes.
BroderickCPagnamentaFForsterR. Dressings and topical agents for arterial leg ulcers. Cochrane Database Syst Rev2020; 1(1): CD001836.
2.
HerberORSchneppWRiegerMA. A systematic review on the impact of leg ulceration on patients’ quality of life. Health Qual Life Outcome2007; 5: 44.
3.
SchneiderCStratmanSKirsnerRS. Lower extremity ulcers. Med Clin2021; 105(4): 663–679.
4.
NelsonEAAdderleyU. Venous leg ulcers. Clin Evid2016; 2016: 1902.
5.
JärbrinkKNiGSönnergrenH, et al.Prevalence and incidence of chronic wounds and related complications: a protocol for a systematic review. Syst Rev2016; 5(1): 152.
6.
ProbstSWellerCDBobbinkP, et al.Prevalence and incidence of venous leg ulcers-a protocol for a systematic review. Syst Rev2021; 10(1): 148.
7.
De MaeseneerMGKakkosSKAherneT, et al.Editor’s choice - European society for vascular surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs. Eur J Vasc Endovasc Surg2022; 63(2): 184–267.
8.
KarnasulaVM. Management of ulcers in lymphoedematous limbs. Indian J Plast Surg2012; 45(2): 261–265.
9.
PintoNRUbillaMZamoraY, et al.Leucocyte- and platelet-rich fibrin (L-PRF) as a regenerative medicine strategy for the treatment of refractory leg ulcers: a prospective cohort study. Platelets2018; 29(5): 468–475.
10.
LäuchliSBayardIHafnerJ, et al.Unterschiedliche Abheilungsdauer und Häufigkeit der Hospitalisation bei Ulcus cruris verschiedener Ursachen [Healing times and the need for hospitalization for leg ulcers of different etiologies]. Hautarzt2013; 64: 917–922.
11.
DohanEDMAndiaIZumsteinMA, et al.Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. Muscles Ligaments Tendons J2014; 4(1): 3–9.
12.
DohanEDMRasmussonLAlbrektssonT. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol2009; 27(3): 158–167.
13.
PavlovicVCiricMJovanovicV, et al.Platelet-rich fibrin: basics of biological actions and protocol modifications. Open Med (Wars)2021; 16(1): 446–454.
14.
PavlovicVCiricMJovanovicV, et al.Platelet Rich Plasma: a short overview of certain bioactive components. Open Med (Wars)2016; 11(1): 242–247.
15.
DohanDMChoukrounJDissA, et al.Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod2006; 101(3): e37–e44.
16.
GianniniSCieloABonanomeL, et al.Comparison between PRP, PRGF and PRF: lights and shadows in three similar but different protocols. Eur Rev Med Pharmacol Sci2015; 19(6): 927–930.
17.
KobayashiEFlückigerLFujioka-KobayashiM, et al.Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Invest2016; 20(9): 2353–2360.
18.
ChenJWanYLinY, et al.Platelet-rich fibrin and concentrated growth factors as novel platelet concentrates for chronic hard-to-heal skin ulcers: a systematic review and Meta-analysis of randomized controlled trials. J Dermatol Treat2022; 33(2): 613–621.
19.
HeLLinYHuX, et al.A comparative study of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on the effect of proliferation and differentiation of rat osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod2009; 108(5): 707–713.
20.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021; 372: n71.
21.
SterneJACSavovićJPageMJ, et al.RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019; 366: l4898.
22.
SterneJAHernánMAReevesBC, et al.ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016; 355: i4919.
23.
GodaAA. Autogenous leucocyte-rich and platelet-rich fibrin for the treatment of leg venous ulcer: a randomized control study. Egypt J Surg2018; 37(3): 316–321.
24.
SomaniARaiR. Comparison of efficacy of autologous platelet-rich fibrin versus saline dressing in chronic venous leg ulcers: a randomised controlled trial. J Cutan Aesthetic Surg2017; 10(1): 8–12.
25.
YuvasriGRaiR. Comparison of efficacy of autologous platelet-rich fibrin versus Unna’s paste dressing in chronic venous leg ulcers: a comparative study. Indian Dermatol Online J2020; 11(1): 58–61.
26.
DorjayKSinhaS. Platelet-rich fibrin in nonhealing leg ulcers: a simple and effective therapeutic option. J Cutan Aesthetic Surg2021; 14(2): 160–165.
27.
JørgensenBKarlsmarkTVogensenH, et al.A pilot study to evaluate the safety and clinical performance of Leucopatch, an autologous, additive-free, platelet-rich fibrin for the treatment of recalcitrant chronic wounds. Int J Low Extrem Wounds2011; 10(4): 218–223.
28.
GameFJeffcoateWTarnowL, et al.LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. Lancet Diabetes Endocrinol2018; 6(11): 870–878.
29.
TabatabaeiFAghamohammadiZTayebiL. In vitro and in vivo effects of concentrated growth factor on cells and tissues. J Biomed Mater Res A2020; 108(6): 1338–1350.
30.
PravinAJSSridharVSrinivasanBN. Autologous platelet rich plasma (PRP) versus leucocyte-platelet rich fibrin (L-PRF) in chronic non-healing leg ulcers – a randomised, open labelled, comparative study. J Evol Med Dent Sci2016; 5(102): 7460–7462.
31.
CrisciA. The L-PRF membrane (fibrin rich in platelets and leukocytes) and its derivatives (A-PRF, I-PRF) are useful as a source of stem cells in regenerative wound therapy: experimental work on the horse. Regen Med Ther2019; 3(1): 37–45.
32.
DashoreSChouhanKNandaS, et al.Platelet-rich fibrin, preparation and use in dermatology. Indian Dermatol Online J2021; 12(Suppl 1): S55–S65.
33.
Fujioka-KobayashiMMironRJHernandezM, et al.Optimized platelet-rich fibrin with the low-speed concept: growth factor release, biocompatibility, and cellular response. J Periodontol2017; 88(1): 112–121.
34.
MasukiHOkuderaTWatanebeT, et al.Growth factor and pro-inflammatory cytokine contents in platelet-rich plasma (PRP), plasma rich in growth factors (PRGF), advanced platelet-rich fibrin (A-PRF), and concentrated growth factors (CGF). Int J Implant Dent2016; 2(1): 19.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
